COVID-19 Clinical Trial
Official title:
Randomized Open-label Multicenter Parallel-group Study of Efficacy and Safety of TL-FVP-t vs. Standard of Care Therapy in Patients With Mild to Moderate Coronavirus Disease (SARS-CoV-2/COVID-19)
Verified date | January 2023 |
Source | R-Pharm |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Randomized open-label multicenter parallel-group study of efficacy and safety of TL-FVP-t vs. standard of care therapy in patients with mild to moderate coronavirus disease (SARS-CoV-2/COVID-19)
Status | Completed |
Enrollment | 168 |
Est. completion date | August 4, 2020 |
Est. primary completion date | July 29, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: 1. Informed consent form signed. 2. Males and females aged 18-60 years; 3. Diagnosis of coronavirus disease caused by SARS-CoV-2 (COVID-19) in a mild or moderate form (without respiratory failure). 4. Duration of infection symptoms shall be no more than 6 days before randomization. 5. SARS-CoV-2 infection should be verified by PCR at the screening. 6. Ability to follow the protocol and fulfill all the clinical study procedures. 7. Ability and willingness of the subjects and their sexual partners with retained childbearing potential to use reliable contraception methods throughout the study and for 3 months after the treatment completion. 8. Willingness not to take alcohol throughout the study. Exclusion Criteria: 1. Age < 18 and > 60 years. 2. Any etiotropic therapy of coronavirus SARS-CoV-2 (COVID-19) infection prior to the study. 3. Moderate infection with respiratory failure, severe or extremely severe SARS-CoV-2 (COVID-19) disease. 4. Respiratory failure (RR > 30/min, SpO2 = 93 %) or the need for mechanical ventilation at the screening. 5. Decreased level of consciousness (disorientation of place, time and personality), agitation at the screening. 6. Unstable hemodynamics (systolic BP < 100 mm Hg or diastolic BP < 60 mm Hg) found at the screening. 7. Subtotal diffuse ground-glass induration of pulmonary tissue and pulmonary consolidation combined with reticular changes; involvement of = 75 % of lung parenchyma; hydrothorax (CT findings corresponding to = CT-4 according to Department of Health of Moscow guidelines). 8. Presence of comorbidities: 1. moderate or severe chronic obstructive pulmonary disease or asthma; 2. severe chronic cardiovascular disorders (arrhythmia or conduction disorders, implanted pacemaker device, myocardial infarction or unstable angina in the medical history, heart failure); 3. immunocompromised subjects (HIV, cancer, autoimmune diseases, immunodepressant therapy); 4. severe obesity (body mass index [BMI] = 40); 5. diabetes mellitus; 6. chronic renal failure; 7. chronic moderate or severe hepatic disorders. 9. Any of the following abnormal laboratory tests at the screening: AST or ALT level > 2.5 x upper normal level (UNL), platelet count < 50?109/L. 10. Any history findings which, in the investigator's opinion, may complicate the interpretation of the study results or generate an additional risk for the subject due to his/her participation in the study. 11. More than 2 CT diagnostic procedures within the last 6 months prior to randomization (except for chest CT no earlier than 4 days prior to enrollment). 12. The subject takes the products significantly inhibiting CYP28?, and administration those products cannot be interrupted for the study duration. 13. Malabsorption syndrome or another clinically relevant gastrointestinal disease which may affect the study product absorption (uncontrollable vomiting, diarrhea, ulcerative colitis, etc.). 14. Pregnancy or breast-feeding; women with probable pregnancy at the screening, those planning to conceive during the study. 15. Known (from the history) or suspected alcohol or psychotropic drug abuse; medicinal or illicit drug addiction. 16. Mental disorders including those in the medical history. 17. Condition or disease which, according to the investigator or medical monitor, will compromise the subject's safety or affect assessment of the study product safety. |
Country | Name | City | State |
---|---|---|---|
Russian Federation | Medical center LLC "Neuroprofi" | Korolev | |
Russian Federation | Federal budgetary institution of science "Central Research Institute of Epidemiology" of Russian Federal Supervision Service for Consumer Rights Protection and People's Welfare | Moscow | |
Russian Federation | Medical centers JSC "Medsi Group of Companies" | Moscow | |
Russian Federation | State budgetary institution of health care of the city of Moscow "City Clinical Hospital ?52 of the Moscow City Healthcare Department" | Moscow | |
Russian Federation | State budgetary institution of health care of the city of Moscow "City Clinical Hospital ?67 n.a. LA Vorokhobova of the Moscow City Healthcare Department" | Moscow | |
Russian Federation | State budgetary institution of health care of the city of Moscow "Infectious Diseases Clinical Hospital ?1 of the Moscow City Healthcare Department" | Moscow | |
Russian Federation | Medical center LLC "Medical Center Eco-safety" | Saint Petersburg | |
Russian Federation | St. Petersburg State Budgetary Healthcare Institution "City Hospital No. 40 of the Kurortny District" | Saint Petersburg | |
Russian Federation | Budgetary healthcare institution of the Voronezh region "Voronezh Regional Clinical Hospital No. 1" | Voronezh | |
Russian Federation | State Budgetary Healthcare Institution of the Moscow Region "Zhukovskaya City Clinical Hospital". | Zhukovskiy |
Lead Sponsor | Collaborator |
---|---|
R-Pharm |
Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time to clinical improvement | To determine the effect of TL-FVP-t vs. SOC on time to clinical improvement. The clinical improvement is defined as reduction on at least 1 score of patient clinical status according to WHO 8-category Ordinal Scale for Clinical Improvement compared to screening | through Day 28 | |
Primary | Time to viral clearance | To determine the effect of TL-FVP-t vs. SOC on time to viral clearance of SARS-CoV-2 virus as measured by PCR in oropharyngeal sampling | through Day 28 | |
Secondary | Rate of clinical improvement at separate time points | To determine the effect of TL-FVP-t vs. SOC on proportion of subjects (%) with clinical improvement according to WHO 8-category Ordinal Scale for Clinical Improvement | Day 7 | |
Secondary | Rate of viral clearance at separate time points | To determine the effect of TL-FVP-t vs. SOC on a proportion of subjects (%) with viral clearance of SARS-CoV-2 virus as measured by PCR in oropharyngeal sampling at separate time points | Days 5 and 7 | |
Secondary | Time to body temperature normalization | To determine the effect of TL-FVP-t vs. SOC on time to body temperature normalization determined as body temperature < 37°C without antipyretics for at least 48 hours. | through Day 28 | |
Secondary | Rate of resolution of lung changes on CT | To determine the effect of TL-FVP-t vs. SOC on a proportion of subjects (%) with resolution of lung changes on CT | Day 14 | |
Secondary | Rate of adverse drug reactions (ADR) and serious ADR | To determine the effect of TL-FVP-t vs. SOC on a proportion of subjects (%) with ADR and serious ADR | through Day 28 | |
Secondary | Rate of severe ADR | To determine the effect of TL-FVP-t vs. SOC on a proportion of subjects (%) with severe ADR | through Day 28 | |
Secondary | Rate therapy termination due to ADR | To determine the effect of TL-FVP-t vs. SOC on a proportion of subjects (%) discontinued therapy due ADR | through Day 28 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|